The Developing Story of Predictive Biomarkers in Colorectal Cancer

• Published in: Journal of personalized medicine Vol. 9; no. 1; p. 12
• Main Authors: Boussios, Stergios, Ozturk, Mehmet Akif, Moschetta, Michele, Karathanasi, Afroditi, Zakynthinakis-Kyriakou, Nikolaos, Katsanos, Konstantinos H, Christodoulou, Dimitrios K, Pavlidis, Nicholas
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 07-02-2019; MDPI
• Subjects: Antibodies; Apoptosis; Biomarkers; Cancer therapies; Cell cycle; Cell death; Chemotherapy; Colorectal cancer; Colorectal carcinoma; Drug resistance; Epidermal growth factor; Epigenetics; Immunotherapy; Inflammation; Lymphocytes; Malignancy; MAP kinase; Medical prognosis; Metastases; Metastasis; Microsatellite instability; Minimal residual disease; miRNA; Mortality; Mutation; Next-generation sequencing; Patients; PD-1 protein; Phenotypes; Precision medicine; Protein kinase; Review; Risk groups; Solid tumors; Surgery; Therapeutic targets; Tumor cells; Tumors; colorectal cancer; prognostic and predictive markers; biomarkers; treatment resistance
• ISSN: 2075-4426; 2075-4426
• DOI: 10.3390/jpm9010012

Colorectal cancer (CRC) is the third most common malignancy worldwide. Surgery remains the most important treatment for non-metastatic CRC, and the administration of adjuvant chemotherapy depends mainly on the disease stage, which is still the strongest prognostic factor. A refined understanding of the genomics of CRC has recently been achieved thanks to the widespread use of next generation sequencing with potential future therapeutic implications. Microsatellite instability (MSI) has been suggested as a predictive marker for response to anti-programmed-cell-death protein 1 (PD-1) therapy in solid tumors, including CRC. It should be noted that not all cancers with MSI phenotype respond to anti-PD-1 immunotherapy, highlighting the urgent need for even better predictive biomarkers. Mitogen-Activated Protein Kinase (
) pathway genes
,
, and
represent important molecular targets and could serve as independent prognostic biomarkers in CRC, and identify those who potentially benefit from anti-epidermal growth factor receptor (EGFR) treatment. Emerging evidence has attributed a significant role to inflammatory markers including blood cell ratios in the prognosis and survival of CRC patients; these biomarkers can be easily assessed in routine blood exams and be used to identify high-risk patients or those more likely to benefit from chemotherapy, targeted therapies and potentially immunotherapy. Analysis of cell-free DNA (cfDNA), circulating tumor cells (CTC) and/or micro RNAs (miRNAs) could provide useful information for the early diagnosis of CRC, the identification of minimal residual disease and, the evaluation of the risk of recurrence in early CRC patients. Even the selection of patients suitable for the new targeted therapy is becoming possible with the use of predictive miRNA biomarkers. Finally, the development of treatment resistance with the emergence of chemo-resistance clones after treatment remains the most important challenge in the clinical practice. In this context it is crucial to identify potential biomarkers and therapeutic targets which could lead to development of new and more effective treatments.